Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Canaccord Genuity reiterated coverage of Galmed Pharmaceuticals with a rating of Buy and set a new price target of $21.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of Galmed Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $29.00 previously
6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
6-K - Galmed Pharmaceuticals Ltd. (0001595353) (Filer)
TEL AVIV, Israel, Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, reports financial results for the three and nine months ended September 30, 2025 and recent developments. Financial Summary – Third Quarter 2025 vs. Third Quarter 2024 Cash and cash equivalents, short term deposits, restricted cash and marketable debt securities totaled approximately $19.2 million as of September 30, 2025, compared to approximately $15.4 million at December 31, 2024.Net loss amounted to approximately $2.0 million, or $0.33 per share, for th
The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tablets The new unexpected PK profile allows for a once daily therapeutic regimen thus potentially improving long term adherence and expected to significantly reduce the drug cost of goods RAMAT-GAN, Israel, Nov. 18, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced meaningful top-line results from Galmed's AM-001 Study
DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Markets open this morning with a distinctly biotech-heavy narrative delivering milestone developments. Zymeworks and Jazz Drop Landmark Phase 3 Data: Ziihera Positioned as New HER2 Standard in First-Line GEA The biggest headline of the morning comes from Zymeworks (NASDAQ:ZYME), after partners Jazz Pharmaceuticals and BeOne Medicines unveiled positive top-line results from the Phase 3 HERIZON-GEA-01 study evaluating Ziihera (zanidatamab-hrii) in front-line HER2-positive gastroesophageal adenocarcinoma (GEA). Why it matters: This is the first Phase 3 trial to show superiority over the long-standing regimen trastuzumab + chemotherapy, positioning
TEL AVIV, Israel, Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, reports financial results for the three and nine months ended September 30, 2025 and recent developments. Financial Summary – Third Quarter 2025 vs. Third Quarter 2024 Cash and cash equivalents, short term deposits, restricted cash and marketable debt securities totaled approximately $19.2 million as of September 30, 2025, compared to approximately $15.4 million at December 31, 2024.Net loss amounted to approximately $2.0 million, or $0.33 per share, for th
TEL AVIV, Israel, Aug. 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three and six months ended June 30, 2025 and recent developments. Recent Business Updates In August 2025, Galmed announced that it has adopted a digital asset management strategy as part of a new treasury investment policy and capital allocation initiative to enhance capital efficiency and drive shareholder value. Accordingly, the Company established a Crypto Committee of the Board, which is evaluating and, if appropriate, will oversee
TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments. Key Recent Developments Announced First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer ModelsSigned Term Sheet for the Development of Novel Semaglutide Sublingual FormulationRaised $6.5 million since the beginning of 2025. Company's current cash balance is $20.1 millionFinancial Summary – First Quarter 2025 vs. First Quarte
SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)
SC 13G/A - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)
SC 13G - Galmed Pharmaceuticals Ltd. (0001595353) (Subject)